Search

everythinglearnresearchcommunity

for

Search:↓

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

CTCL patients can safely continue treatment during COVID-19 with proper safety measures.

Using CD123 to detect certain immune cells helps diagnose a type of hair loss condition.

Lipid-antigen stimulation may play a role in folliculotropic mycosis fungoides.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

Monoclonal antibody B72.3 selectively reacts with certain dog tissues, mainly in the gastrointestinal and respiratory tracts.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

Enhancing Tregs can protect against alopecia areata.

Tph cells are linked to the severity of systemic lupus erythematosus.

Dual TCR Treg cells are common in various mouse tissues and show diverse characteristics.

ICL is a condition with low CD4+ T cells like AIDS but not caused by HIV, and normal CD4+ T cell counts may vary between men and women.

Tislelizumab can cause cutaneous lupus erythematosus.

Increasing Treg cells in the skin does not cure hair loss from alopecia areata in mice.

IL-18 signaling helps mature Tregs move into the thymus.

Immunomodulatory therapies are effective for treating cutaneous lymphoma, particularly in early stages.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Folliculotropic mycosis fungoides has unique molecular features and cell interactions that could guide targeted therapy.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

Tcf3 helps cells move and heal wounds by controlling lipocalin 2.

Dual TCR Treg cells are common in mouse tissues and vary by location.

Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.

Three characteristics of plasmacytoid dendritic cells help tell apart lupus-related hair loss from LPP.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

IL-18 signaling helps mature Tregs move into the thymus.